The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Can IL-6 Predict Sarilumab Response?

Can IL-6 Predict Sarilumab Response?

January 2, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—Previously, the RA-MOBILITY (NCT01061736) and SARIL-RA-MONARCH (NCT02332590) clinical trials showed that sarilumab had significantly improved efficacy when treating patients with rheumatoid arthritis (RA) compared with adalimumab and methotrexate. Recent post-hoc analyses of the trials examined if a patient’s baseline interleukin (IL) 6 levels were associated with radiographic and clinical responses to sarilumab vs. other treatments.

You Might Also Like
  • Sarilumab Is Effective for RA, Pregabalin Fails to Meet Study Endpoint & Ibuprofen Can Be Administered with a Patch
  • News Updates for Diclofenac Sodium, Denosumab & Sarilumab
  • Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
Also By This Author
  • Clinical Trials Ongoing for Brodalumab

Presented during the 2018 ACR/ARHP Annual Meeting, the new analyses demonstrate that, at baseline, RA patients with high IL-6 levels and higher disease activity and joint damage had a better response to 200 mg of sarilumab than to methotrexate monotherapy, and adalimumab treatment in patients who had low IL-6 levels at baseline.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For the studies, baseline IL-6 levels were measured using a validated assay in patients (N=1,193) randomized to 150 mg of subcutaneous sarilumab every two weeks plus methotrexate, 200 mg of subcutaneous sarilumab every two weeks plus methotrexate, or placebo plus methotrexate. Additionally, 300 patients were randomized to 200 mg sarilumab every two weeks or 40 mg of adalimumab every two weeks. Efficacy was compared between and within treatment groups according to baseline IL-6 tertile, using linear and logistic regression.

During the MOBILITY trial, placebo plus methotrexate-treated patients in the high tertile developed more joint damage than patients in the low tertile. Sarilumab-treated patients with high IL-6 levels demonstrated improved clinical signs and symptoms and had less radiographic evidence of joint damage compared with methotrexate-monotherapy-treated patients with high IL-6 levels. In SARIL-RA-MONARCH, sarilumab-treated patients with high IL-6 levels were more likely to achieve disease remission at Week 24 compared with adalimumab-treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Data show that high IL-6 may be better than high C-reactive protein levels at predicting sarilumab efficacy outcomes in RA patients. In this study, across clinical and radiographic endpoints, patients with elevated baseline levels of IL-6 had a greater response to sarilumab treatment compared with methotrexate or adalimumab than patients with normal IL-6 levels. The authors suggest a prospective study to confirm these data.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Boyapati A, Msihid J, Schwartzman S, et al. High baseline serum IL-6 identies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response [abstract]. Arthritis Rheumatol. 2018 Oct; 70 (suppl 10).

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, Methotrexate, sarilumab

You Might Also Like:
  • Sarilumab Is Effective for RA, Pregabalin Fails to Meet Study Endpoint & Ibuprofen Can Be Administered with a Patch
  • News Updates for Diclofenac Sodium, Denosumab & Sarilumab
  • Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
  • Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)